Literature DB >> 15193974

Idiopathic calcium oxalate urolithiasis: risk factors and conservative treatment.

Sonja Lewandowski1, Allen L Rodgers.   

Abstract

Idiopathic calcium oxalate urolithiasis is a frequent and recurrent multifactorial disease. This review focuses on urinary and dietary risk factors for this disease and conservative strategies for rectifying them. Dietary oxalate and calcium and their respective urinary excretions have been extensively investigated during the last 10 years. Urinary oxalate has emerged as the most important determinant of calcium oxalate crystallization while the role of urinary calcium has shifted to bone balance and osteoporosis. Dietary calcium restriction increases urinary oxalate and contributes to a negative bone balance. It has therefore been abandoned as a means to reduce the risk of calcium oxalate kidney stone formation. Calcium oxalate kidney stone patients are advised to increase their fluid intake to achieve a urine volume of 2 l or more; the recommended calcium intake is 800-1200 mg/day; high oxalate foods should be restricted; daily protein intake should be between 0.8 and 1 g/kg body weight/day; essential fats should be included; vegetable and fruit (except oxalate-rich vegetables) intake should be increased. The use of calcium supplements has potential benefits but needs to be examined further. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193974     DOI: 10.1016/j.cccn.2004.03.009

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  22 in total

1.  Effect of indigenous plant extracts on calcium oxalate crystallization having a role in urolithiasis.

Authors:  Fauzia Yasir; Muhammad A Waqar
Journal:  Urol Res       Date:  2011-06-04

2.  Oxalate and its handling in a low stone risk vs a stone-prone population group.

Authors:  Sonja Lewandowski; Allen L Rodgers; Norbert Laube; Gerd von Unruh; Diana Zimmermann; Albrecht Hesse
Journal:  World J Urol       Date:  2005-11-06       Impact factor: 4.226

3.  Wu-Ling-San formula prophylaxis against recurrent calcium oxalate nephrolithiasis - a prospective randomized controlled trial.

Authors:  Eugene Lin; Lin Ho; Mao-Sheng Lin; Min-Ho Huang; Wen-Chi Chen
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-08-12

4.  Hypercalciuria, hyperoxaluria, and hypocitraturia screening from random urine samples in patients with calcium lithiasis.

Authors:  Miguel Angel Arrabal-Polo; Salvador Arias-Santiago; María Sierra Girón-Prieto; Felix Abad-Menor; Fernando López-Carmona Pintado; Armando Zuluaga-Gomez; Miguel Arrabal-Martin
Journal:  Urol Res       Date:  2012-04-07

5.  Assessment of mineral intake by kidney stone patients of Kangra District, Himachal Pradesh with respect to their gender, age and income.

Authors:  Madhvi Awasthi; S R Malhotra
Journal:  Indian J Pediatr       Date:  2013-03-24       Impact factor: 1.967

6.  Plasma oxalate level in pediatric calcium stone formers with or without secondary hyperoxaluria.

Authors:  Przemysław Sikora; Bodo Beck; Małgorzata Zajaczkowska; Bernd Hoppe
Journal:  Urol Res       Date:  2009-01-30

7.  Association study of DGKH gene polymorphisms with calcium oxalate stone in Chinese population.

Authors:  Yong Xu; Guohua Zeng; Zanlin Mai; Lili Ou
Journal:  Urolithiasis       Date:  2014-08-01       Impact factor: 3.436

Review 8.  The elementome of calcium-based urinary stones and its role in urolithiasis.

Authors:  Krishna Ramaswamy; David W Killilea; Pankaj Kapahi; Arnold J Kahn; Thomas Chi; Marshall L Stoller
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

9.  Assessment of crystallization risk formulas in pediatric calcium stone-formers.

Authors:  Przemysław Sikora; Małgorzata Zajaczkowska; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2009-03-31       Impact factor: 3.714

10.  Family history in stone disease: how important is it for the onset of the disease and the incidence of recurrence?

Authors:  Hakan Hasbey Koyuncu; Faruk Yencilek; Bilal Eryildirim; Kemal Sarica
Journal:  Urol Res       Date:  2010-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.